Pictet Asset Management (Switzerland)’s Bionano Genomics BNGO Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-70	Closed	-$46.4K	–	1968
2023 Q1	$46.4K	Hold	70	–	–	﹤0.01%	1949
2022 Q4	$61K	Buy	70 +36	+106%	+$45.3K	﹤0.01%	1947
2022 Q3	$37K	Hold	34	–	–	﹤0.01%	1537
2022 Q2	$28K	Hold	34	–	–	﹤0.01%	1558
2022 Q1	$52K	Hold	34	–	–	﹤0.01%	1652
2021 Q4	$60K	Hold	34	–	–	﹤0.01%	1691
2021 Q3	$111K	Buy	+34	New	+$119K	﹤0.01%	1677

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s BNGO Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) sold out of Bionano Genomics (BNGO) in Q2 2023, closing a stake of 70 shares — an estimated $46.4K sold.

Pictet Asset Management (Switzerland) first reported a position in BNGO in Q3 2021 and held it in 7 quarters. The position peaked at $111K in Q3 2021. 108 funds tracked by Wall St. Rank hold BNGO as of Q2 2023.

Pictet Asset Management (Switzerland) reported no remaining Bionano Genomics position as of Q2 2023 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 70 Bionano Genomics shares in Q2 2023, an estimated $46.4K.
Pictet Asset Management (Switzerland) first reported a position in Bionano Genomics in Q3 2021 and held it in 7 quarters.
Pictet Asset Management (Switzerland)'s Bionano Genomics position peaked at $111K in Q3 2021.
108 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.